Edition:
United Kingdom

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
23 Feb 2018
Change (% chg)

$-0.02 (-3.14%)
Prev Close
$0.61
Open
$0.62
Day's High
$0.62
Day's Low
$0.54
Volume
144,032
Avg. Vol
90,423
52-wk High
$4.59
52-wk Low
$0.54

Chart for

About

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $43.12
Shares Outstanding(Mil.): 14.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

30 Jan 2018

BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018

* FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING Source text: (http://bit.ly/2EaJQ01) Further company coverage:

29 Dec 2017

BRIEF-Fibrocell Science Q3 loss per share $‍0.02​

* Fibrocell reports third quarter 2017 financial results and recent highlights

13 Nov 2017

BRIEF-Fibrocell Science files for common stock offering of up to $23 mln

* Fibrocell Science Inc files for common stock offering of up to $23 million - SEC filing‍​ Source text: (http://bit.ly/2AoC3tG) Further company coverage:

06 Nov 2017

Earnings vs. Estimates